Share This Page
Drugs in ATC Class C04AE
✉ Email this page to a colleague
Drugs in ATC Class: C04AE - Ergot alkaloids
| Tradename | Generic Name |
|---|---|
| ALKERGOT | ergoloid mesylates |
| CIRCANOL | ergoloid mesylates |
| DEAPRIL-ST | ergoloid mesylates |
| ERGOLOID MESYLATES | ergoloid mesylates |
| GERIMAL | ergoloid mesylates |
| HYDERGINE | ergoloid mesylates |
| HYDERGINE LC | ergoloid mesylates |
| >Tradename | >Generic Name |
Showing 1 to 7 of 7 entries
C04AE Market Analysis and Financial Projection
The market dynamics and patent landscape for ATC Class C04AE (ergot alkaloids) reflect a balance of historical innovation, evolving production techniques, and shifting regulatory and trade environments. Here's a detailed analysis:
Market Dynamics
1. Industry Growth and Segmentation
- Dopamine Agonist Market: Ergot alkaloids (e.g., bromocriptine, cabergoline) form the second-largest segment, valued at $1.31 billion in 2024 with a projected 5.7% CAGR through 2030[11]. Demand is driven by Parkinson’s disease (affecting ~10 million globally) and hyperprolactinemia.
- Peripheral Vasodilators: This market includes ergot alkaloids like dihydroergocristine, used for cerebrovascular disorders. Europe’s competitive landscape features Novartis, Pfizer, and GSK, with growth linked to aging populations and cardiovascular disease prevalence[12].
2. Trade and Production
- Global Trade: In 2023, global trade of rye ergot alkaloids and derivatives reached $75.2M, led by Czechia ($39.6M exports) and South Korea ($6.7M imports)[15]. A 19.4% decline from 2022 underscores market volatility.
- Production: Annual output includes 5,000–8,000 kg of ergopeptines and 10,000–15,000 kg of lysergic acid, primarily via fermentation (60%) and field cultivation[5]. Major producers include Novartis, Boehringer Ingelheim, and Gedeon Richter[1][12].
3. Trends and Challenges
- Generics Dominance: Patent expirations (e.g., ergotamine) have spurred generic production, improving accessibility in developing markets[11].
- Contamination Risks: Ergot alkaloid contamination in grains (e.g., rye, barley) remains a food safety concern, necessitating enhanced monitoring and mitigation strategies[13].
Patent Landscape
1. Historical Innovations
- Isolation Techniques: Arthur Stoll’s 1918 patent (US1394233A) revolutionized ergotamine extraction using acid-alkaline treatments[2]. Later methods, like EP1742953B1, optimized solvent-based isolation (toluene/ethanol)[16].
- Fermentation Advances: US3224945A (1963) introduced submerged fermentation with Claviceps paspali, enabling scalable production[8].
2. Modern Developments
- Synthetic Derivatives: US4230854 (1980) covers non-natural ergot alkaloids synthesized via mutant Claviceps strains and amino acid precursors[4].
- Biosynthesis Research: Genetic analysis of ergot alkaloid clusters (e.g., lpsA gene diversity) is driving strain-specific alkaloid profiling for targeted drug development[6].
3. Key Players
Novartis, Boehringer Ingelheim, and Lek (Slovenia) dominate patent portfolios, focusing on:
- Improved extraction efficiency[16].
- Novel derivatives for enhanced therapeutic profiles[4][17].
Regulatory and Classification Framework
- ATC Classification: C04AE includes ergot alkaloids like dihydroergocristine (DDD: 4 mg oral)[9]. Combinations with calcium channel blockers are excluded[9][10].
- Regional Regulations:
- EU: No binding ergot limits in food, though Germany/Switzerland suggest guidelines[13].
- North America: Strict limits on ergot bodies in grains[13].
Strategic Outlook
- Market Expansion: Generic ergot alkaloids and combination therapies will drive affordability and adherence[11][12].
- Technological Shifts: Advances in fermentation and genetic engineering may reduce contamination risks and enhance yield[5][6].
- Collaborative Mitigation: Stakeholder coordination on surveillance and storage practices is critical to managing food safety risks[13].
Highlight: "Annual world production of ergot alkaloids has been estimated at 5,000–8,000 kg of all ergopeptines...maintained through submerged fermentation and field cultivation." [1]
This synthesis underscores ergot alkaloids' dual role as vital pharmaceuticals and agricultural contaminants, necessitating balanced innovation in production and safety protocols.
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC1637017/
- https://patents.google.com/patent/US1394233A/en
- https://go.drugbank.com/drugs/DB13345
- https://patents.justia.com/patent/4230854
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11493748/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8704706/
- https://eahp.eu/wp-content/uploads/2024/04/Milan-EJHP-abstract-book.pdf
- https://patents.google.com/patent/US3224945A/en
- https://atcddd.fhi.no/atc_ddd_index/?code=C04AE&showdescription=yes
- https://atcddd.fhi.no/atc_ddd_index/?code=N02CA
- https://www.grandviewresearch.com/industry-analysis/dopamine-agonist-market-report
- https://www.transparencymarketresearch.com/peripheral-vasodilator-drugs-market.html
- https://www.digicomply.com/blog/ergot-alkaloids-in-grains
- https://www.pharmacompass.com/active-pharmaceutical-ingredients/ergoline-8-beta-methanol-10-methoxy-1-6-dimethyl-5-bromonicotinate-ester
- https://oec.world/en/profile/hs/rye-ergot-alkaloids-derivatives-in-bulk-salts
- https://patents.google.com/patent/EP1742953B1/en
- https://patents.google.com/patent/GB1485738A/en
More… ↓
